Barclays’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $5.94M | Sell |
|
|||||
|
2025
Q2 | $7.21M | Buy |
|
|||||
|
2025
Q1 | $3.02M | Sell |
|
|||||
|
2024
Q4 | $3.49M | Sell |
|
|||||
|
2024
Q3 | $3.62M | Buy |
|
|||||
|
2024
Q2 | $1.4M | Sell |
|
|||||
|
2024
Q1 | $1.4M | Sell |
|
|||||
|
2023
Q4 | $4.22M | Buy |
|
|||||
|
2023
Q3 | $3.88M | Sell |
|
|||||
|
2023
Q2 | $3.87M | Sell |
|
|||||
|
2023
Q1 | $5.86M | Buy |
|
|||||
|
2022
Q4 | $5.56M | Buy |
|
|||||
|
2022
Q3 | $5.18M | Buy |
|
|||||
|
2022
Q2 | $918K | Sell |
|
|||||
|
2022
Q1 | $1.99M | Sell |
|
|||||
|
2021
Q4 | $3.03M | Buy |
|
|||||
|
2021
Q3 | $1.13M | Sell |
|
|||||
|
2021
Q2 | $1.3M | Sell |
|
|||||
|
2021
Q1 | $2.39M | Buy |
|
|||||
|
2020
Q4 | $730K | Sell |
|
|||||
|
2020
Q3 | $987K | Sell |
|
|||||
|
2020
Q2 | $1.78M | Sell |
|
|||||
|
2020
Q1 | $2.3M | Buy |
|
|||||
|
2019
Q4 | $688K | Sell |
|
|||||
|
2019
Q3 | $669K | Sell |
|
|||||
|
2019
Q2 | $1.37M | Buy |
|
|||||
|
2019
Q1 | $861K | Buy |
|
|||||
|
2018
Q4 | $330K | Sell |
|
|||||
|
2018
Q3 | $345K | Buy |
|
|||||
|
2018
Q2 | $64K | Sell |
|
|||||
|
2018
Q1 | $140K | Buy |
|
|||||
|
2017
Q4 | $116K | Buy |
|
|||||
|
2017
Q3 | $78K | Sell |
|
|||||
|
2017
Q2 | $904K | Buy |
|
|||||
|
2017
Q1 | $208K | Sell |
|
|||||
|
2016
Q4 | $396K | Buy |
|
|||||
|
2016
Q3 | $7K | Sell |
|
|||||
|
2016
Q2 | $52K | Sell |
|
|||||
|
2016
Q1 | $41K | Buy |
|
|||||
|
2015
Q4 | $175K | Sell |
|
|||||
|
2015
Q3 | $887K | Buy |
|
|||||
|
2015
Q2 | $686K | Buy |
|
|||||
|
2015
Q1 | $29K | Sell |
|
|||||
|
2014
Q4 | $75K | Sell |
|
|||||
|
2014
Q3 | $100K | Sell |
|
|||||
|
2014
Q2 | $182K | Buy |
|
|||||
|
2014
Q1 | $103K | Sell |
|
|||||
|
2013
Q4 | $168K | Sell |
|
|||||
|
2013
Q3 | $183K | Sell |
|
|||||
|
2013
Q2 | $262K | Buy |
|